References
- Beedham C. (2002). Molybdenum hydroxylases. In: Ioannides C, ed. Enzyme systems that metabolise drugs and other xenobiotics. New York: John Wiley & Sons, 147–88
- Beumer JH, Rademaker-Lakhai JM, Rosing H, et al. (2005). Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 23:429–36
- Beumer JH, Garner RC, Cohen MB, et al. (2007). Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs 25:327–34
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13
- Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
- Jost LM, Gschwind HP, Jalava T, et al. (2006). Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos 34:1817–28
- King C, Diaz H, Darlene B, et al. (2014). Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs 32:213–26
- Matthews TP, Jones AM, Collins I. (2013). Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies. Expert Opin Drug Discov 8:621–40
- Nakajima M, Nakamura S, Tokudome S, et al. (1999). Azelastine N-demethylation by cytochrome P450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict contribution of multiple CYPs. Drug Metab Dispos 27:1381–91
- Penner N, Klunk LJ, Prakash C. (2009). Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185–203
- Rehmel JF, Heim J, Oluyedun O, et al. (2012) Poster P42: rapid and early identification of P450s involved in test article metabolism. Drug Metab Rev 44:36–152
- Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43
- Weiss GJ, Donehower RC, Iyengar T, et al. (2013). Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after premetrexed 500mg/m(2) every 21 days in patients with cancer. Invest New Drugs 31:136–44
- Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11–23
- Zientek M, Jiang Y, Youdim K, Obach RS. (2010). In vitro-in vivo correlation for intrinsic clearance for drug metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322–7